In October 2014, olaparib (Lynparza, AZN) became the first PARP inhibitor to receive a positive CHMP opinion for European approval for the treatment of recurrent, BRCA mutation-associated ovarian cancer. Several other PARP inhibitors are in clinical trials for breast, ovarian, pancreatic, and other solid tumor cancers.

BRCA testing is currently offered to patients with a family history of BRCA-associated cancers, but testing is not routinely performed on all solid tumors patients. Since mutations in BRCA and other DNA repair proteins may predict response to PARP inhibitors, sponsors of these drug candidates are partnering with diagnostics companies to develop companion diagnostics that could be used to screen patients once PARP inhibitors hit the clinic.

Companies mentioned: Myriad Genetics (MYGN), Foundation Medicine (FMI), AstraZeneca (AZN), Tesaro (TSRO), Clovis (CLVS), AbbVie (ABBV), BioMarin (BMRN).

To download a copy of this infographic, click on the link at the top of the page.

This infographic was developed in conjunction with the forthcoming MedDeviceTracker product. For more information and updates on this product, please provide your information at the MedDeviceTracker website or contact BioMedTracker Client Services by e-mail or telephone at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.

Last infographic update: January 9, 2015